Epidemiological characteristics of chronic respiratory diseases in patients vaccinated against pneumococcal infection

Abstract

The purpose of this study was to analyze prospectively clinical and economic effects of vaccination of COPD patients using conjugated pneumococcal vaccine PСV13 (Prevenar 13). Methods. The study involved 394 male patients treated in the Teaching Hospital No.4 and Chelyabinsk Pulmonary Center in 2012 – 2016. Number of COPD exacerbations, hospitalizations and cases of pneumonia was analyzed; dyspnea and lung function were also measured; BODE, DOSE, and ADO prognostic indices were calculated. The cost-efficacy of vaccination was assessed. Results. Vaccination with PСV13 vaccine allowed stabilization basic respiratory functional parameters. In a year after the vaccination, BODE, DOSE, and ADO indices significantly decreased and this effect maintained during four years. Number of infectious exacerbations and pneumonia cases significantly decreased in 4 years after vaccination in non-smoking patients. Conclusion. The prognostic indices are a reliable tool to evaluate efficacy of treatment. Vaccination allowed saving up to RUR 394.3 million (78.5%) per a year due to reduction in number of COPD exacerbations and rate of pneumonia.